Menarini chooses Italy for its new €150 million manufacturing site.

Menarini Group and Stemline Therapeutics Inc., a commercial-stage biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics, (Nasdaq: STML) today announced a definitive agreement under which Menarini Group will acquire Stemline in a transaction valued up to $677 million.

The Board of Directors has appointed Mrs. Elcin Barker Ergun as CEO of Menarini Group

The 23rd Menarini International Fair Play Awards will take place in Florence. An evening dedicated...

Menarini Ricerche today announced the publication of the results of a non-clinical study...